Abstract
Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Current Drug Safety
Title:Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Volume: 8 Issue: 1
Author(s): Antonio Siniscalchi, Luca Gallelli, Simona Loizzo, Avenoso Tiziana, Emilio Russo and Giovambattista De Sarro
Affiliation:
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Abstract: Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Export Options
About this article
Cite this article as:
Siniscalchi Antonio, Gallelli Luca, Loizzo Simona, Tiziana Avenoso, Russo Emilio and Sarro Giovambattista De, Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome, Current Drug Safety 2013; 8 (1) . https://dx.doi.org/10.2174/1574886311308010010
DOI https://dx.doi.org/10.2174/1574886311308010010 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis of Poison-Frog Alkaloids and Their Pharmacological Effects at Neuronal Nicotinic Acetylcholine Receptors
Current Chemical Biology Schiff Bases of Benzothiazol-2-ylamine and Thiazolo[5,4-b] pyridin-2-ylamine as Anticonvulsants: Synthesis, Characterization and Toxicity Profiling*
Central Nervous System Agents in Medicinal Chemistry Gene and Gene-Environment Risk Factors in Sudden Undexpected Death in Infants
Current Pediatric Reviews Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome
Current Alzheimer Research α/βHydrolase Fold: An Update
Protein & Peptide Letters The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry The Prophylactic Use of Antiepileptic Drugs in Patients Scheduled for Neurosurgery
Current Pharmaceutical Design Kernel-Based Feature Selection Techniques for Transport Proteins Based on Star Graph Topological Indices
Current Topics in Medicinal Chemistry Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Therapeutic Drug Monitoring of Phenytoin by Simple, Rapid, Accurate, Highly Sensitive and Novel Method and Its Clinical Applications
Current Pharmaceutical Biotechnology The Role of Innate Immune System Receptors in Epilepsy Research
CNS & Neurological Disorders - Drug Targets Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Molecular Mechanisms of Cytochrome P450 Induction: Potential for Drug-Drug Interactions
Current Protein & Peptide Science Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry Editorial [Hot Topic: When Can a Drug be Declared “Safe”? (Guest Editors: Frank M.C. Besag & Seetal Dodd)]
Current Drug Safety Applications and Synthesis of the Antiepileptic Drug Oxcarbazepine and Related Structures
Current Organic Chemistry The Role of Newer Antiglutamatergic Agents as Mood-Stabilizers in Bipolar Disorder
Current Drug Targets R-Type Voltage-Gated Ca<sup>2+</sup> Channels in Cardiac and Neuronal Rhythmogenesis
Current Molecular Pharmacology PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment
Current Neuropharmacology Genetic Polymorphism of Organic Anion and Cation Transporters: Pharmacokinetic and Pharmacodynamic Consequences in Pharmacotherapy
Current Pharmacogenomics